The Claim
In aged female 3xTg mice, 7 days of istradefylline treatment is associated with a 52% reduction in cortical PRMT4 protein levels and a 50% reduction in ADMA, restoring both to levels observed in healthy aged C57BL/6 mice, suggesting that A2A receptor blockade may normalize the PRMT4-ADMA pathway linked to nitric oxide dysregulation in Alzheimer’s disease.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In aged female 3xTg mice, 7 days of istradefylline treatment reduces cortical PRMT4 protein levels by 52% and ADMA levels by 50%, returning both to levels seen in healthy aged C57BL/6 mice.
See the scientific wording
In aged female 3xTg mice, 7 days of istradefylline treatment was associated with a 52% reduction in cortical PRMT4 protein levels and a 50% reduction in ADMA, restoring both to levels seen in healthy aged C57BL/6 mice, suggesting that A2A receptor blockade may normalize the PRMT4-ADMA pathway linked to nitric oxide dysregulation in Alzheimer’s disease.
A drug blocks a receptor in the brain that is overactive in Alzheimer’s-like disease. This causes a methylating enzyme to decrease, which in turn lowers a molecule that blocks nitric oxide production. With more nitric oxide available, blood vessels in the brain widen, improving blood flow and reducing damage from protein buildup.
What the research says
1 studyIn older female mice with Alzheimer’s-like symptoms, a drug called istradefylline helped fix two broken molecules (PRMT4 and ADMA) that were clogging blood vessels in the brain, bringing them back to healthy levels.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.